• Manila Office:02-8221222
  • Kuala Lumpur Office:+60 10-898 8919
  • Indonesia Office ↓
  • +62 812-978-978-59 , +62 813-8183-7924
Request Information
E-mail

On April 11 & April 12, the forum which was organized by ASEAN Academic Committee of Minimally Invasive Therapy of Tumor and co-organized by Modern Cancer Hospital Guangzhou China, was held at Bali. Near one hundred influential tumor experts from China and Indonesia gathered at the forum and shared the new achievements of innovative minimally invasive technology. Also, they published two latest research achievement of tumor therapy---- Radioactive Particle Implantation Technology Jointed with Chemotherapy and Radiation and Multiple Targeted Antitumor Immune Cells. Twenty four cancer patients, who successfully fought against cancer, shared their anticancer experience and brought new hope to other tumor patients.

Authoritative Tumor Experts Published New Anticancer New Technologies

In the ASEAN Academic Committee of Minimally Invasive Therapy, tumor experts, Professor Peng Xiaochi and Professor Li Xiaoshi, respectively published two latest research achievements of tumor therapy---- radioactive particle implantation technology jointed with chemotherapy and radiation and multiple targeted antitumor immune cell, which gave more choices for patients to choose and brought new hope for them to fight against cancer.

The Radioactive Particle Implantation Technology Jointed with Chemotherapy and Radiation

Under the guidance of CT or B-mode Ultrasound, the radiotherapy particle and chemotherapy particle will be implanted into the tumor in turn so that it can realize the synchronization of radiotherapy and chemotherapy. The application of radiotherapy particle and chemotherapy particle make chemotherapy medicine take sensitization effect of radiotherapy and get dual anticancer efficacy.

Multiple Targeted Antitumor Immune Cell

The multiple-targeted antitumor immune cell is an immune technology of new biological cell which is based on the original DC-CIK technology. DC-CIK unicellular therapy contains two main "anticancer cells", DC and CIK, which are put back to the patients' body. The multiple-targeted antitumor immune cell increases the number to 5 from 2 and applies five nuclear cell jointed therapy, DC, CTL,NK, γδT, CD3AK so that it builds up multi-angle to fight against and kill tumor. Two people cooperated to fight against enemies before and now five "brothers" joint to fight against cancer which bring better efficacy.

More Anticancer Technology >>

Honorary Award

Media Report

Co-organized Media